PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia Sustained Drug Delivery Technology

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia,

Related Keywords

Australia ,Melbourne ,Victoria ,San Francisco ,California ,United States ,Australian ,Kostenloser Wertpapierhandel ,Russell Tait ,Michael Coote ,Prezia Sustained Drug Delivery Technology ,Prnewswire Polyactiva Pty Ltd ,Brandon Capital Medical Research Commercialisation Fund ,Horizons Forum ,Secondary Efficacy Endpoints Met ,Intra Ocular Pressure ,Activa Pty Ltd ,Primary Open Angle Glaucoma ,Chief Executive Officer ,Annual Glaucoma ,Associate Professor Michael Coote ,Melbourne Eye Specialists ,About Polyactiva ,Brandon Capital ,Medical Research Commercialisation Fund ,Polyactiva ,Nnounces ,Positive ,Hase ,Trial ,Results ,Nose ,Cohort ,A5108 ,Secular ,Implant ,Rezia ,Sustained ,Drug ,Delivery ,Technology ,